Matches in SemOpenAlex for { <https://semopenalex.org/work/W2614901353> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2614901353 endingPage "S9" @default.
- W2614901353 startingPage "S9" @default.
- W2614901353 abstract "Introduction: Animal and early clinical studies have shown that regulatory T cell (Treg) therapy can prevent graft-versus-host disease (GVHD) following hematopoietic stem cell transplant. Despite these promising results, challenges remain in administering Treg therapy including the difficulty in isolating pure Tregs and expanding them to a therapeutic dose. We have previously found that the thymus, which is routinely removed during pediatric cardiac surgery, is a plentiful source of Tregs. These Tregs can be easily isolated, and can prevent xenoGVHD in mice. However, to use this therapy in humans, standard GMP-compliant methods for isolation and large-scale expansion of thymic Tregs must be developed. Methods: CD4+CD8-CD25+ thymic Tregs were isolated from pediatric thymuses using GMP-compatible magnetic bead-based separation. Tregs were expanded using artificial antigen-presenting cells or GMP-compatible antibody tetramer complexes that stimulate CD3 and CD28, with or without additional activation of CD2. Cells were cultured with rapamycin and IL-2, and were restimulated after 7 days without rapamycin. Results: Thymic Tregs expand in vitro when cultured with tetrameric antibody complexes. About 50-fold expansion was achieved using the anti-CD3/CD28/CD2 antibody tetramers, which represents the expansion that will be necessary to reach a clinically relevant dose. A higher expansion rate was obtained using the anti-CD3/CD28/CD2 antibody tetramer complexes than the anti-CD3/CD28. Cells cultured with these antibody tetramers express high levels of FOXP3, similar levels of Treg-characteristic markers as those expanded with artificial antigen-presenting cells, and do not produce inflammatory cytokines. Conclusion: Thymic Tregs can be isolated and expanded with GMP-compliant methods. Once the protocol is optimized, we can transfer our protocols to a GMP facility for further process development and to generate data required for a clinical trial application. We are the first group to pursue clinical application using allogeneic thymic Tregs, which provide an opportunity for an “off-the-shelf” therapy to treat GVHD. Canadian National Transplant Research Program." @default.
- W2614901353 created "2017-05-26" @default.
- W2614901353 creator A5004888467 @default.
- W2614901353 creator A5010498011 @default.
- W2614901353 creator A5016614279 @default.
- W2614901353 creator A5038480610 @default.
- W2614901353 creator A5076144019 @default.
- W2614901353 creator A5085736100 @default.
- W2614901353 date "2017-05-01" @default.
- W2614901353 modified "2023-09-25" @default.
- W2614901353 title "Development of GMP-Compatible Protocols for Thymus-Derived Regulatory T Cell Expansion" @default.
- W2614901353 doi "https://doi.org/10.1097/01.tp.0000520303.10595.5e" @default.
- W2614901353 hasPublicationYear "2017" @default.
- W2614901353 type Work @default.
- W2614901353 sameAs 2614901353 @default.
- W2614901353 citedByCount "0" @default.
- W2614901353 crossrefType "journal-article" @default.
- W2614901353 hasAuthorship W2614901353A5004888467 @default.
- W2614901353 hasAuthorship W2614901353A5010498011 @default.
- W2614901353 hasAuthorship W2614901353A5016614279 @default.
- W2614901353 hasAuthorship W2614901353A5038480610 @default.
- W2614901353 hasAuthorship W2614901353A5076144019 @default.
- W2614901353 hasAuthorship W2614901353A5085736100 @default.
- W2614901353 hasConcept C114684123 @default.
- W2614901353 hasConcept C147483822 @default.
- W2614901353 hasConcept C148125776 @default.
- W2614901353 hasConcept C159654299 @default.
- W2614901353 hasConcept C167672396 @default.
- W2614901353 hasConcept C203014093 @default.
- W2614901353 hasConcept C2776090121 @default.
- W2614901353 hasConcept C2779727006 @default.
- W2614901353 hasConcept C502942594 @default.
- W2614901353 hasConcept C71924100 @default.
- W2614901353 hasConcept C79484868 @default.
- W2614901353 hasConcept C86803240 @default.
- W2614901353 hasConcept C8891405 @default.
- W2614901353 hasConceptScore W2614901353C114684123 @default.
- W2614901353 hasConceptScore W2614901353C147483822 @default.
- W2614901353 hasConceptScore W2614901353C148125776 @default.
- W2614901353 hasConceptScore W2614901353C159654299 @default.
- W2614901353 hasConceptScore W2614901353C167672396 @default.
- W2614901353 hasConceptScore W2614901353C203014093 @default.
- W2614901353 hasConceptScore W2614901353C2776090121 @default.
- W2614901353 hasConceptScore W2614901353C2779727006 @default.
- W2614901353 hasConceptScore W2614901353C502942594 @default.
- W2614901353 hasConceptScore W2614901353C71924100 @default.
- W2614901353 hasConceptScore W2614901353C79484868 @default.
- W2614901353 hasConceptScore W2614901353C86803240 @default.
- W2614901353 hasConceptScore W2614901353C8891405 @default.
- W2614901353 hasIssue "5S-3" @default.
- W2614901353 hasLocation W26149013531 @default.
- W2614901353 hasOpenAccess W2614901353 @default.
- W2614901353 hasPrimaryLocation W26149013531 @default.
- W2614901353 hasRelatedWork W1557803273 @default.
- W2614901353 hasRelatedWork W2066839598 @default.
- W2614901353 hasRelatedWork W2081996451 @default.
- W2614901353 hasRelatedWork W2092704936 @default.
- W2614901353 hasRelatedWork W2368899435 @default.
- W2614901353 hasRelatedWork W2373867616 @default.
- W2614901353 hasRelatedWork W2384344522 @default.
- W2614901353 hasRelatedWork W2391818597 @default.
- W2614901353 hasRelatedWork W4283165273 @default.
- W2614901353 hasRelatedWork W4362541563 @default.
- W2614901353 hasVolume "101" @default.
- W2614901353 isParatext "false" @default.
- W2614901353 isRetracted "false" @default.
- W2614901353 magId "2614901353" @default.
- W2614901353 workType "article" @default.